Assessment of gastric mucosa conditions changes in patients with gastric neuroendocrine neoplasia type 1 during gastroprotective therapy

#4555

Introduction: Currently, the incidence of gastric neuroendocrine neoplasia (gNEN) has increased significantly. Most gNEN are developed on the background of chronic atrophic gastritis (about 90%). Despite this, the role of chronic atrophic gastritis treatment (gastroprotective therapy) in dynamic of gNEN remains unexplored.

Aim(s): To present the results of observation of patients with gNEN type 1 during gastroprotective therapy.

Materials and methods: 46 gNEN type 1 patients were included for 6 years. All of the patients had gastroprotective therapy in regime: rebamipide 100 mg, 3 times a day for 8 weeks three times a year. The dynamics of the disease after conservative treatment was measured using using endoscopy data and the results of follow-up biopsy according to the OLGA (Operative Link on Gastritis Assessment) staging system.

Conference:

Presenting Author: Konyakhina A

Authors: Konyakhina A, Feidorov I, Salimgereeva D, Petrova A,

Keywords: gNEN, atrophic gastritis, OLGA, rebamipide,